|
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Nov 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management |
Nov 2020 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
Nov 2020 |
Cells |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease |
Nov 2020 |
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria |
Oct 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
Oct 2020 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study |
Oct 2020 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
Oct 2020 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
